T

Instil Bio
D

TIL

29.890
USD
4.43
(17.39%)
Market Closed
Volume
2,480
EPS
-13
Div Yield
-
P/E
-3
Market Cap
195,058,762
News

Title: Instil Bio

Sector: Healthcare
Industry: Biotechnology
Instil Bio Inc is a clinical-stage biopharmaceutical company focused on developing a cell therapy pipeline of autologous tumor infiltrating lymphocyte, or TIL, therapies for the treatment of patients with cancer. It is also engaged in developing a novel class of genetically engineered TIL therapies using its Co-Stimulatory Antigen Receptor, or CoStAR, platform. Its pipeline includes ITIL-306 which expresses a CoStAR molecule designed to recognize FR, a tumor-associated antigen that is expressed on numerous solid tumors, including ovarian cancer, uterine cancer, NSCLC, and renal cancer.